US Biotechnology Small/Mid Cap: EHA 2026: Highlights from SNDX, KURA and NRIX across AML and CLL

Research evidence excerpt

US Biotechnology Small/Mid Cap: EHA 2026: Highlights from SNDX, KURA and NRIX across AML and CLL

Global Research

15 June 2026ab

US Biotechnology Small/Mid Cap Equities

North AmericaEHA 2026: Highlights from SNDX, KURA and

NRIX across AML and CLL Healthcare

David Dai

Analyst

david.dai@ubs.com

Key Takeaways +1-212-713 6241

We highlight other EHA oral/poster presentations from SNDX, KURA, Sumitomo Bridget Holle

Pharma, and NRIX. SNDX presented updated Revuforj data from NUP98r R/R AML and Associate Analyst

Revuforj + venetoclax + Inqovi in R/R AML. KURA published updated data from KOMET- bridget.holle@ubs.com

007 in R/R AML. Sumitomo Pharma's menin inhibitor enzomenib Ph2 monotherapy +1-212-649 8207

trial update with competitive readthroughs to SNDX/KURA. NRIX presented updated

data for bexobrutideg in CLL/SLL, including longer follow-up from Ph1a late-line dose

escalation and initial activity in Ph1b earlier-line cohorts.

SNDX - Revumenib Demonstrated Consistent Response in NUP98r R/R AML

SNDX reported updated Phase 1 AUGMENT-101 data evaluating revumenib

monotherapy in patients with relapsed/refractory (R/R) NUP98 Rearranged (NUP98r)

AML. Results demonstrated clinically meaningful activity in this small patient subgroup

(n=6), with a 50% ORR, 50% CRc, and 17% CR/CRh broadly consistent with the

outcomes observed in the label population (Figure 1). Data supports Revuforj's activity in

a subset of high-risk aggressive AML. Safety appeared manageable overall with

moderate rates of Gr.3+ myelosuppression including febrile neutropenia (23%),

neutrophil count decreased (19%), and thrombocytopenia (15%) all below rates

reported in the Revuforj label. We also note there were no treatment-related AEs leading